Literature DB >> 11941552

Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.

Elizabeth L Corbett1, Gavin J Churchyard, Salome Charalambos, Badara Samb, Vicky Moloi, Tim C Clayton, Alison D Grant, Jill Murray, Richard J Hayes, Kevin M De Cock.   

Abstract

A cohort of 1792 human immunodeficiency virus (HIV)-positive and 2970 HIV-negative South African miners was observed for 12 months starting in February 1998. All-cause hospitalizations and deaths were significantly associated with HIV infection (respective unadjusted incidence rate ratios, 2.9 and 9.2; respective 95% confidence intervals, 2.5-3.4 and 5.5-16.0). Tuberculosis (TB), bacterial pneumonia, cryptococcosis, and trauma were the major causes of admission for HIV-positive patients, whereas Pneumocystis carinii pneumonia was an uncommon cause (respective admission rates, 8.5, 6.9, 2.2, 6.0, and 0.53 admissions per 100 person-years). Enteritis, bronchitis, urinary tract infections, and soft-tissue infections were also significantly associated with HIV infection. Cryptococcosis caused 44% of deaths among HIV-positive patients. Trauma was the main hazard for HIV-negative men, causing 42% of admissions and 60% of deaths. A broad range of infectious conditions is significantly associated with HIV infection in South African miners. Identification and implementation of effective prophylactic regimens are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11941552     DOI: 10.1086/339540

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  59 in total

1.  HIV in Africa: Challenges and Directions for the Next Decade.

Authors:  Bruce L Gilliam; Devang Patel; Rohit Talwani; Zelalem Temesgen
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

2.  Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.

Authors:  Salome Charalambous; Alison D Grant; Craig Innes; Christopher J Hoffmann; Rob Dowdeswell; Jan Pienaar; Katherine L Fielding; Gavin J Churchyard
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

3.  Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?

Authors:  Joseph N Jarvis; Thomas S Harrison; Elizabeth L Corbett; Robin Wood; Stephen D Lawn
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

4.  Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans.

Authors:  Oliver W Liu; Cheryl D Chun; Eric D Chow; Changbin Chen; Hiten D Madhani; Suzanne M Noble
Journal:  Cell       Date:  2008-10-03       Impact factor: 41.582

Review 5.  Antifungal drug discovery through the study of invertebrate model hosts.

Authors:  R Pukkila-Worley; E Holson; F Wagner; E Mylonakis
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

6.  Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey.

Authors:  Rashida A Ferrand; Tsitsi Bandason; Praise Musvaire; Natasha Larke; Kusum Nathoo; Hilda Mujuru; Chiratidzo E Ndhlovu; Shungu Munyati; Frances M Cowan; Diana M Gibb; Elizabeth L Corbett
Journal:  PLoS Med       Date:  2010-02-02       Impact factor: 11.069

7.  Cryptococcal meningitis in Senegal: epidemiology, laboratory findings, therapeutic and outcome of cases diagnosed from 2004 to 2011.

Authors:  Doudou Sow; Roger Clément Tine; Khadime Sylla; Mansata Djiba; Cheikh Tidiane Ndour; Thérèse Dieng; Jean Louis Ndiaye; Babacar Faye; Daouda Ndiaye; Oumar Gaye; Yémou Dieng
Journal:  Mycopathologia       Date:  2013-10-25       Impact factor: 2.574

8.  Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.

Authors:  Josephine V J Lightowler; Graham S Cooke; Portia Mutevedzi; Richard J Lessells; Marie-Louise Newell; Martin Dedicoat
Journal:  PLoS One       Date:  2010-01-07       Impact factor: 3.240

9.  Pneumocystis pneumonia in HIV-positive adults, Malawi.

Authors:  Joep J G van Oosterhout; Miriam K Laufer; M Arantza Perez; Stephen M Graham; Nelson Chimbiya; Phillip C Thesing; Miriam J Alvarez-Martinez; Paul E Wilson; Maganizo Chagomerana; Eduard E Zijlstra; Terrie E Taylor; Christopher V Plowe; Steven R Meshnick
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

10.  Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

Authors:  Dominique J Pepper; Suzaan Marais; Robert J Wilkinson; Feriyl Bhaijee; Gary Maartens; Helen McIlleron; Virginia De Azevedo; Helen Cox; Cheryl McDermid; Simiso Sokhela; Janisha Patel; Graeme Meintjes
Journal:  BMC Infect Dis       Date:  2010-03-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.